tirzepatide cvot trial 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What SURPASS-CVOT — Leicester Diabetes Centre

GLP-1 receptor agonist medications Health & Medicine Analysis There are pros and cons for weight loss medications like Ozempic Drugs like Mounjaro and Wegovy have led to a sudden shift in treatment, but also to a lot of questions about how we think about and treat obesity Health & Medicine Analysis What are drugs like Ozempic doing to the brains of people that binge eat

Dushay, an additional cause of weight gain in the forties and beyond

Patients with certain medical conditions should be evaluated first

Lean mass preservation supports fat loss without excessive muscle degradation

That hormone, called GLP-1, sends a signal to your brain that you are full and slows how quickly food leaves your stomach, so you stay satisfied longer